[54]
In particular, Novopharm says that Prothonotary Milczynski should not have dismissed the effect of the overarching principle of confidentiality with respect to drug submissions. As a result of this principle, and in accordance with the legislative mandate of s. 6(8) of the
Regulations
, protective orders are routinely sought and generally granted in proceedings under the
Regulations
. As the Federal Court of Appeal stated in
AB Hassle et al. v. Canada (Minister of National Health and Welfare) et al.
(2000), 253 N.R. 284; 5 C.P.R.(4th) 149 (F.C.A.) ("
AB Hassle
"):
"The perceived confidentiality of information flowing from a drug manufacturer to the Department of National Health and Welfare is a cornerstone of the system pertaining to the processing of new drug submissions and the issuance of notices of compliance. For this system to function effectively, the confidential nature of the relationship ought to be honoured and maintained to the extent possible."